Fig. 1 · Structure

Documents & Downloads

(E/Z)-4-hydroxy Tamoxifen

Cat. No. A12532 CAS 68392-35-8

Estrogen receptor antagonist

(E/Z)-4-hydroxy Tamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer.

In Stock

Publications for (E/Z)-4-hydroxy Tamoxifen

4 publications citing this product

  1. Yuanqin Zhang, .et al. , Cancers (Basel), 2023, Dec 2;15(23):5691 PMID: 38067394
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  3. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  4. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Estrogen receptor  
Human Endogenous Metabolite  

In Vitro Studies

In isolated adult rat cardiac myocytes, acute exposure to Sigma H6278 4-hydroxytamoxifen at 5–10 µM reduced shortening and calcium-transient amplitude and slowed mechanical relaxation. Resting sarcomere length and resting calcium signal showed no significant changes. These cellular effects warrant attention when interpreting experiments using micromolar 4-hydroxytamoxifen; they do not establish an in-vivo toxicity threshold. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Acute effects on isolated adult rat cardiac myocyte contraction and calcium handling

Cell-based study · Isolated adult female Sprague-Dawley rat ventricular myocytes [1]

At 5 and 10 µM, 4OHT reduced sarcomere shortening and calcium-transient peak height, and prolonged time to 50% mechanical relaxation. Resting sarcomere length, resting calcium signal and time to 50% calcium decay showed no significant changes in Figure 4. A separate cell-counting readout showed fewer stimulated cells contracting at 10 µM by 45 minutes. These are acute isolated-cell observations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Sarcomere shortening and relaxationQualitative comparison 5 µM: reduced peak height (P < 0.05), longer time to 50% relaxation (P < 0.05); 10 µM: reduced peak height (P < 0.001), longer time to 50% relaxation (P < 0.01). Resting length: no significance indicated.[1]
Calcium-transient amplitude and kineticsQualitative comparison Peak calcium signal reduced at 5 and 10 µM (P < 0.01 for each). No significant change indicated for resting calcium signal or time to 50% calcium decay.[1]
Percentage of contracting rod-shaped myocytes relative to baselineQualitative comparison At 45 min, 10 µM reduced contracting-cell percentage versus 0 µM (P < 0.001). No exact percentage extracted from the curve.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.5, 1, 3, 5 and 10 µM in concentration-response assays; Figure 3B shows 0, 5 and 10 µM.
Exposure duration
Sarcomere data collected 15–45 min after stimulation began; calcium: 3 min stimulation followed by 20 min collection; contracting-cell counts through 45 min.
Method
Acute application in modified Tyrode’s solution; different concentrations tested in random order; fresh working stocks used because precipitation occurred over time.
Vehicle
Methanol stock; total vehicle held constant across concentrations, with 0 µM vehicle control. Final vehicle fraction not stated in read text.
Reported limits
Exact isomer ratio of the experimental lot and A12532 lot equivalence were not established. SI Table S2 not retrieved; no tabulated means borrowed or estimated.
Methods and source locations

Compound reported in the paper: 4-Hydroxytamoxifen; Compound label in the paper: 4OHT; Sigma-Aldrich H6278

Results apply to the reported H6278 material and isolated rat-cell conditions; mixture ratios and supplier lots may differ. No in-vivo cardiac toxicity or Adooq lot validation is claimed.

Methods §§Treatments, Sarcomere Length Measurements, Myocyte Contractility, Calcium Handling, Statistical Analysis; Results §4-Hydroxytamoxifen; Figures 3B and 4B–H

Sarcomere shortening and relaxation: Ionoptix; 0.2 Hz, 36 ± 1°C; mean ± SEM, N = 45–50 cells/treatment from four preparations; Dunnett comparisons against 0 µM. — Figure 4B–D and caption; Methods §§Sarcomere Length Measurements, Statistical Analysis

Calcium-transient amplitude and kinetics: Fura-2AM, 360/380 nm ratio; 0.5 Hz, 36 ± 1°C; mean ± SEM, N = 38–42 cells/treatment from three preparations; Dunnett comparisons against 0 µM. — Figure 4F–H and caption; Methods §§Calcium Handling, Statistical Analysis

Percentage of contracting rod-shaped myocytes relative to baseline: Counting 30–50 cells per field at baseline, 5, 15, 30 and 45 min; 0.2 Hz; mean ± SEM; N = 3–4 counting experiments/treatment; repeated-measures ANOVA/Bonferroni. — Figure 3B and caption; Methods §§Myocyte Contractility, Statistical Analysis

Specifications

Manufacturer Adooq Bioscience
Actions Modulator
CAS Number 68392-35-8
Applications Estrogen receptor antagonist
Formula C26H29NO2
Molecular Weight 387.51
Synonyms Afimoxifene
SMILES
OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)/CC)C=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 72 mg/mL (185.8 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Michelle L Asp, Joshua J Martindale, Joseph M Metzger. Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling PLoS ONE (2013). PMID: 24205315 DOI: 10.1371/journal.pone.0078768 Source material

Publications

4 publications citing this product

  1. Yuanqin Zhang, .et al. , Cancers (Basel), 2023, Dec 2;15(23):5691 PMID: 38067394
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  3. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  4. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Added to your cart

View Cart Checkout
Loading...